ArticleNature communications2020
Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of GeneXpert EV assay for the rapid diagnosis of enteroviral meningitis: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2022Pooled it
- Identification of key amino acids defining conformational neutralizing epitopes of coxsackievirus A5 using monoclonal antibody escape mutants.Frontiers in immunology · 2026Article
- Establishment and application of a wild neonatal mouse model infected with an Echovirus 30 isolate.Virology journal · 2025Article
- Foot-and-mouth disease virus antigenic landscape and reduced immunogenicity elucidated in atomic detail.Nature communications · 2024Article
- Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.Veterinary research · 2024Review
- Sequence-specific nanoparticle barcode strategy for multiplex human enterovirus typing.Nature communications · 2024Article
- Article
- Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy.Frontiers in immunology · 2024Review
- Comprehensive profiling of neutralizing polyclonal sera targeting coxsackievirus B3.Nature communications · 2023Article
- In silico epitope prediction and evolutionary analysis reveals capsid mutation patterns for enterovirus B.PloS one · 2023Article
- Structure of Human Enterovirus 70 and Its Inhibition by Capsid-Binding Compounds.Journal of virology · 2022Article
- Comparison of Physical and Biochemical Characterizations of SARS-CoV-2 Inactivated by Different Treatments.Viruses · 2022Article
- Atomic Structures of Coxsackievirus B5 Provide Key Information on Viral Evolution and Survival.Journal of virology · 2022Article
- Structures of Foot-and-Mouth Disease Virus with Bovine Neutralizing Antibodies Reveal the Determinant of Intraserotype Cross-Neutralization.Journal of virology · 2021Article
- Structural basis for neutralization of an anicteric hepatitis associated echovirus by a potent neutralizing antibody.Cell discovery · 2021Article
- Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection.Cell research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echovirus 30 (E30), a serotype of Enterovirus B (EV-B), recently emerged as a major causative agent of aseptic meningitis worldwide. E30 is particularly devastating in the neonatal population and currently no vaccine or antiviral therapy is available. Here we characterize two highly potent E30-specific monoclonal antibodies, 6C5 and 4B10, which efficiently block binding of the virus to its attachment receptor CD55 and uncoating receptor FcRn. Combinations of 6C5 and 4B10 augment the sum of their individual anti-viral activities. High-resolution structures of E30-6C5-Fab and E30-4B10-Fab define the location and nature of epitopes targeted by the antibodies. 6C5 and 4B10 engage the capsid loci at the north rim of the canyon and in-canyon, respectively. Notably, these regions exhibit antigenic variability across EV-Bs, highlighting challenges in development of broad-spectrum antibodies. Our structures of these neutralizing antibodies of E30 are instructive for development of vaccines and therapeutics against EV-B infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.